Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
- Citation:
- Cancer vol 113 (11) 3137-45
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 504
- Children:
- None
- Pharmas:
- Grants:
- CA16359, CA21060, CA33601, CA60138, CA77651
- Corr. Author:
- Authors:
- William Kevin Kelly Susan Halabi Aymen Elfiky San-San Ou Jeff Bogart Michael Zelefsky Eric Small
- Networks:
- Study
- CALGB-99811
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Aged, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Combined Modality Therapy, Disease-Free Survival, Drug Administration Schedule, Estramustine, Feasibility Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Paclitaxel, Prostate-Specific Antigen, Prostatic Neoplasms